Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Two Class III directors elected through 2029: Thomas J. Schuetz and Richard S. Lindahl.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Two Class III directors elected through 2029: Thomas J. Schuetz and Richard S. Lindahl
- CohnReznick ratified as independent auditor for year ending December 31, 2026, with 137.9M votes supporting
- Executive compensation approved on an advisory basis, with 118.0M votes for and 1.8M against
- Annual advisory votes on executive compensation adopted, supported by 118.3M votes
- High broker non-votes of 21.3M on director and compensation proposals reduce insight into uninstructed shareholder preferences
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.